| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute-On-Chronic Liver Failure | 16 | 2024 | 72 | 6.700 |
Why?
|
| Carcinoma, Hepatocellular | 21 | 2025 | 933 | 5.230 |
Why?
|
| Liver Neoplasms | 22 | 2025 | 1316 | 4.780 |
Why?
|
| Liver Cirrhosis | 31 | 2025 | 859 | 3.890 |
Why?
|
| End Stage Liver Disease | 9 | 2023 | 182 | 3.220 |
Why?
|
| Liver Transplantation | 16 | 2024 | 1042 | 2.480 |
Why?
|
| Fatty Liver | 10 | 2013 | 190 | 2.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 17 | 2023 | 403 | 2.050 |
Why?
|
| Liver Diseases | 3 | 2024 | 368 | 1.750 |
Why?
|
| Early Detection of Cancer | 4 | 2025 | 362 | 1.720 |
Why?
|
| Hepatitis C | 3 | 2023 | 367 | 1.580 |
Why?
|
| Hepatitis C, Chronic | 3 | 2021 | 344 | 1.190 |
Why?
|
| Humans | 97 | 2025 | 125362 | 1.000 |
Why?
|
| Postal Service | 1 | 2024 | 9 | 0.930 |
Why?
|
| Patient Navigation | 1 | 2024 | 25 | 0.910 |
Why?
|
| Graft Survival | 3 | 2024 | 532 | 0.830 |
Why?
|
| Isoflavones | 1 | 2022 | 43 | 0.780 |
Why?
|
| Severity of Illness Index | 14 | 2023 | 2909 | 0.780 |
Why?
|
| Prognosis | 11 | 2024 | 4686 | 0.770 |
Why?
|
| Duodenal Diseases | 2 | 2019 | 34 | 0.760 |
Why?
|
| Gastroparesis | 1 | 2022 | 65 | 0.750 |
Why?
|
| Mass Screening | 2 | 2025 | 785 | 0.720 |
Why?
|
| Exercise Therapy | 1 | 2022 | 156 | 0.690 |
Why?
|
| Frailty | 1 | 2022 | 105 | 0.680 |
Why?
|
| Quality of Life | 5 | 2022 | 1909 | 0.670 |
Why?
|
| Telemedicine | 2 | 2023 | 436 | 0.660 |
Why?
|
| Prevalence | 12 | 2021 | 2467 | 0.640 |
Why?
|
| Alcohol Drinking | 3 | 2021 | 344 | 0.640 |
Why?
|
| Palliative Care | 2 | 2020 | 433 | 0.630 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 76 | 0.620 |
Why?
|
| Organ Transplantation | 1 | 2021 | 168 | 0.620 |
Why?
|
| Lipase | 4 | 2020 | 94 | 0.610 |
Why?
|
| Syphilis | 1 | 2019 | 97 | 0.610 |
Why?
|
| Penicillins | 1 | 2019 | 154 | 0.610 |
Why?
|
| Publication Bias | 1 | 2018 | 14 | 0.600 |
Why?
|
| Endoscopy, Digestive System | 1 | 2019 | 152 | 0.590 |
Why?
|
| Probiotics | 2 | 2018 | 215 | 0.590 |
Why?
|
| Risk Assessment | 6 | 2025 | 3431 | 0.570 |
Why?
|
| Observational Studies as Topic | 3 | 2023 | 88 | 0.530 |
Why?
|
| Antiviral Agents | 5 | 2025 | 768 | 0.530 |
Why?
|
| Membrane Proteins | 5 | 2020 | 1538 | 0.500 |
Why?
|
| Testosterone | 1 | 2021 | 558 | 0.500 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2018 | 205 | 0.490 |
Why?
|
| Sodium | 3 | 2020 | 299 | 0.470 |
Why?
|
| Anxiety | 2 | 2023 | 944 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1272 | 0.440 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2015 | 76 | 0.440 |
Why?
|
| Ascites | 3 | 2024 | 93 | 0.430 |
Why?
|
| Middle Aged | 27 | 2025 | 26763 | 0.430 |
Why?
|
| Aged | 21 | 2025 | 19722 | 0.420 |
Why?
|
| Deglutition Disorders | 1 | 2015 | 133 | 0.410 |
Why?
|
| Protein Phosphatase 1 | 1 | 2013 | 51 | 0.410 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2022 | 98 | 0.390 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 73 | 0.390 |
Why?
|
| United States | 15 | 2024 | 10909 | 0.390 |
Why?
|
| Depression | 1 | 2020 | 1232 | 0.380 |
Why?
|
| Vitamin D | 1 | 2013 | 165 | 0.370 |
Why?
|
| Treatment Outcome | 12 | 2025 | 12287 | 0.360 |
Why?
|
| Retrospective Studies | 22 | 2024 | 16369 | 0.360 |
Why?
|
| Cross-Sectional Studies | 8 | 2022 | 3408 | 0.360 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2013 | 561 | 0.360 |
Why?
|
| Male | 31 | 2025 | 61566 | 0.350 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2880 | 0.350 |
Why?
|
| Cohort Studies | 8 | 2022 | 4828 | 0.330 |
Why?
|
| Gastrointestinal Microbiome | 4 | 2024 | 698 | 0.330 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2024 | 668 | 0.330 |
Why?
|
| Organ Dysfunction Scores | 2 | 2020 | 48 | 0.320 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 819 | 0.320 |
Why?
|
| Inflammation | 1 | 2017 | 1445 | 0.320 |
Why?
|
| Hepacivirus | 2 | 2021 | 248 | 0.320 |
Why?
|
| Helicobacter pylori | 3 | 2024 | 1324 | 0.320 |
Why?
|
| Helicobacter Infections | 3 | 2024 | 1267 | 0.320 |
Why?
|
| Liver | 6 | 2021 | 1749 | 0.320 |
Why?
|
| Diet | 3 | 2022 | 1138 | 0.310 |
Why?
|
| Ultrasonography | 5 | 2021 | 939 | 0.310 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2019 | 23 | 0.310 |
Why?
|
| Biopsy | 4 | 2023 | 1244 | 0.310 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2021 | 26 | 0.310 |
Why?
|
| Colon | 3 | 2021 | 352 | 0.300 |
Why?
|
| Gastroenterology | 2 | 2025 | 201 | 0.290 |
Why?
|
| Gastroesophageal Reflux | 2 | 2024 | 327 | 0.290 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 604 | 0.280 |
Why?
|
| Female | 28 | 2025 | 66821 | 0.280 |
Why?
|
| Secondary Prevention | 2 | 2020 | 216 | 0.270 |
Why?
|
| Myotomy | 2 | 2017 | 19 | 0.270 |
Why?
|
| Nutrition Surveys | 5 | 2020 | 295 | 0.270 |
Why?
|
| Alcohol Abstinence | 2 | 2017 | 16 | 0.270 |
Why?
|
| Adult | 22 | 2023 | 29543 | 0.270 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 303 | 0.260 |
Why?
|
| Risk Factors | 13 | 2025 | 10298 | 0.260 |
Why?
|
| Intestinal Mucosa | 3 | 2021 | 781 | 0.250 |
Why?
|
| Bacteria | 2 | 2019 | 481 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2022 | 678 | 0.240 |
Why?
|
| Weight Loss | 3 | 2023 | 482 | 0.230 |
Why?
|
| Paracentesis | 1 | 2024 | 17 | 0.230 |
Why?
|
| Virus Activation | 1 | 2025 | 87 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 1118 | 0.220 |
Why?
|
| Hernia, Hiatal | 1 | 2024 | 56 | 0.220 |
Why?
|
| Tissue Donors | 3 | 2022 | 483 | 0.220 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2023 | 68 | 0.220 |
Why?
|
| Fundoplication | 1 | 2024 | 69 | 0.220 |
Why?
|
| Hepatitis B virus | 1 | 2025 | 130 | 0.220 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 57 | 0.220 |
Why?
|
| Allografts | 2 | 2021 | 176 | 0.220 |
Why?
|
| Herniorrhaphy | 1 | 2024 | 81 | 0.220 |
Why?
|
| Hypertension, Portal | 2 | 2024 | 78 | 0.210 |
Why?
|
| Hepatic Encephalopathy | 2 | 2023 | 79 | 0.210 |
Why?
|
| Gastroenterologists | 1 | 2023 | 11 | 0.210 |
Why?
|
| Early Diagnosis | 1 | 2024 | 184 | 0.210 |
Why?
|
| Disease Progression | 4 | 2024 | 2084 | 0.210 |
Why?
|
| Hepatitis B | 1 | 2025 | 161 | 0.210 |
Why?
|
| Bacterial Infections | 2 | 2016 | 307 | 0.200 |
Why?
|
| Morbidity | 1 | 2023 | 248 | 0.200 |
Why?
|
| Anti-Obesity Agents | 1 | 2022 | 41 | 0.200 |
Why?
|
| Plasma Exchange | 1 | 2023 | 84 | 0.200 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 2057 | 0.190 |
Why?
|
| Hemochromatosis | 1 | 2022 | 33 | 0.190 |
Why?
|
| Physical Fitness | 1 | 2022 | 90 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 2430 | 0.190 |
Why?
|
| Genetic Pleiotropy | 1 | 2021 | 24 | 0.190 |
Why?
|
| Genome-Wide Association Study | 3 | 2021 | 1694 | 0.180 |
Why?
|
| Biliary Atresia | 1 | 2024 | 190 | 0.180 |
Why?
|
| Hospital Mortality | 2 | 2024 | 1027 | 0.180 |
Why?
|
| Referral and Consultation | 1 | 2024 | 543 | 0.180 |
Why?
|
| Global Burden of Disease | 1 | 2021 | 26 | 0.180 |
Why?
|
| Bacterial Translocation | 2 | 2024 | 23 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1157 | 0.170 |
Why?
|
| Biomarkers | 3 | 2024 | 3106 | 0.170 |
Why?
|
| Precancerous Conditions | 1 | 2023 | 284 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 443 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2023 | 372 | 0.170 |
Why?
|
| Esophageal Achalasia | 2 | 2017 | 42 | 0.160 |
Why?
|
| Abdominal Cavity | 1 | 2019 | 8 | 0.160 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 649 | 0.160 |
Why?
|
| Hyperkalemia | 1 | 2021 | 67 | 0.160 |
Why?
|
| Treponema pallidum | 1 | 2019 | 50 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2020 | 121 | 0.160 |
Why?
|
| Tissue and Organ Procurement | 1 | 2022 | 222 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2019 | 118 | 0.160 |
Why?
|
| Mutation | 2 | 2022 | 5905 | 0.160 |
Why?
|
| Mortality | 1 | 2020 | 238 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 167 | 0.150 |
Why?
|
| Ablation Techniques | 1 | 2018 | 30 | 0.150 |
Why?
|
| Hemochromatosis Protein | 2 | 2022 | 22 | 0.140 |
Why?
|
| Lymph Nodes | 1 | 2019 | 378 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2021 | 472 | 0.140 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2017 | 11 | 0.140 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 547 | 0.140 |
Why?
|
| Esophagitis, Peptic | 1 | 2017 | 37 | 0.140 |
Why?
|
| Time Factors | 5 | 2021 | 6311 | 0.140 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 118 | 0.130 |
Why?
|
| Radiosurgery | 1 | 2018 | 111 | 0.130 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2016 | 4 | 0.130 |
Why?
|
| Alcohol-Related Disorders | 1 | 2017 | 35 | 0.130 |
Why?
|
| Ileus | 1 | 2016 | 10 | 0.130 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2017 | 44 | 0.130 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2016 | 7 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2023 | 3313 | 0.130 |
Why?
|
| Patient Selection | 1 | 2020 | 696 | 0.130 |
Why?
|
| Esophageal Diseases | 1 | 2016 | 36 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 576 | 0.130 |
Why?
|
| Stomach Diseases | 1 | 2016 | 56 | 0.130 |
Why?
|
| Colectomy | 1 | 2016 | 74 | 0.120 |
Why?
|
| Patient Discharge | 1 | 2019 | 495 | 0.120 |
Why?
|
| Appendectomy | 1 | 2016 | 86 | 0.120 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 156 | 0.120 |
Why?
|
| Prebiotics | 1 | 2015 | 24 | 0.120 |
Why?
|
| Genotype | 3 | 2022 | 2570 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2018 | 650 | 0.120 |
Why?
|
| Terminology as Topic | 1 | 2017 | 224 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 3176 | 0.120 |
Why?
|
| Suture Techniques | 1 | 2016 | 193 | 0.120 |
Why?
|
| Endoscopy | 1 | 2017 | 281 | 0.120 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2015 | 53 | 0.120 |
Why?
|
| Hospitalization | 2 | 2024 | 1791 | 0.120 |
Why?
|
| Mexican Americans | 2 | 2013 | 202 | 0.120 |
Why?
|
| Veterans | 3 | 2024 | 1726 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 2182 | 0.110 |
Why?
|
| Gene Frequency | 2 | 2013 | 729 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3688 | 0.110 |
Why?
|
| Anxiety Disorders | 1 | 2020 | 689 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2017 | 389 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 257 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 730 | 0.110 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1902 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2018 | 543 | 0.110 |
Why?
|
| Young Adult | 7 | 2019 | 9061 | 0.110 |
Why?
|
| Pancreatitis | 1 | 2015 | 133 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 208 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2015 | 153 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6558 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2015 | 353 | 0.100 |
Why?
|
| Contraceptives, Oral | 1 | 2012 | 37 | 0.100 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 259 | 0.100 |
Why?
|
| Menstruation | 1 | 2012 | 29 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2023 | 6141 | 0.100 |
Why?
|
| Hyperuricemia | 1 | 2013 | 38 | 0.100 |
Why?
|
| Sepsis | 1 | 2017 | 484 | 0.100 |
Why?
|
| Uric Acid | 1 | 2013 | 95 | 0.100 |
Why?
|
| alpha-Fetoproteins | 2 | 2023 | 132 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2016 | 547 | 0.090 |
Why?
|
| Obesity | 2 | 2022 | 2252 | 0.090 |
Why?
|
| Cognition | 1 | 2016 | 723 | 0.090 |
Why?
|
| Length of Stay | 3 | 2024 | 1310 | 0.090 |
Why?
|
| Incidence | 1 | 2018 | 3134 | 0.090 |
Why?
|
| Waiting Lists | 2 | 2021 | 227 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2015 | 518 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 779 | 0.080 |
Why?
|
| Asia | 2 | 2021 | 111 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 690 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2021 | 364 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1714 | 0.080 |
Why?
|
| Europe | 2 | 2020 | 359 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 1025 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2013 | 1505 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 5171 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2022 | 1399 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2017 | 241 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2021 | 1172 | 0.050 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2024 | 60 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2023 | 64 | 0.050 |
Why?
|
| Gastroscopy | 1 | 2023 | 100 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 36 | 0.050 |
Why?
|
| Diethylpropion | 1 | 2022 | 2 | 0.050 |
Why?
|
| Phentermine | 1 | 2022 | 7 | 0.050 |
Why?
|
| Liraglutide | 1 | 2022 | 14 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2024 | 126 | 0.050 |
Why?
|
| Research Design | 2 | 2020 | 693 | 0.050 |
Why?
|
| Bupropion | 1 | 2022 | 29 | 0.050 |
Why?
|
| Neurocan | 2 | 2013 | 2 | 0.050 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 2 | 2013 | 27 | 0.050 |
Why?
|
| Naltrexone | 1 | 2022 | 70 | 0.050 |
Why?
|
| Metaplasia | 1 | 2023 | 213 | 0.050 |
Why?
|
| Donor Selection | 1 | 2022 | 54 | 0.050 |
Why?
|
| Prothrombin | 1 | 2022 | 25 | 0.050 |
Why?
|
| Lectins, C-Type | 2 | 2013 | 71 | 0.050 |
Why?
|
| Hydrogels | 1 | 2022 | 84 | 0.050 |
Why?
|
| Ferritins | 1 | 2022 | 100 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 24 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 421 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 14 | 0.050 |
Why?
|
| Sex Factors | 2 | 2017 | 1275 | 0.050 |
Why?
|
| Health Care Rationing | 1 | 2021 | 58 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2025 | 630 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2021 | 162 | 0.040 |
Why?
|
| Simvastatin | 1 | 2021 | 75 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2024 | 385 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1121 | 0.040 |
Why?
|
| Endpoint Determination | 1 | 2020 | 57 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 673 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 252 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2022 | 238 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 209 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 363 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 26 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 442 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 2050 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 231 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 117 | 0.040 |
Why?
|
| Aftercare | 1 | 2019 | 147 | 0.040 |
Why?
|
| Comorbidity | 1 | 2023 | 1528 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 239 | 0.040 |
Why?
|
| Communication | 1 | 2022 | 510 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 1275 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 759 | 0.040 |
Why?
|
| Adolescent | 3 | 2024 | 19430 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 727 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 475 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 2656 | 0.040 |
Why?
|
| Exercise | 1 | 2023 | 814 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 644 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 83 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 530 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 439 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 1129 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2096 | 0.030 |
Why?
|
| Sutures | 1 | 2016 | 64 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 237 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1104 | 0.030 |
Why?
|
| Intraabdominal Infections | 1 | 2015 | 2 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2015 | 12 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2016 | 181 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1113 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 819 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1534 | 0.030 |
Why?
|
| Lysophospholipase | 1 | 2013 | 2 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1065 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1394 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1495 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2013 | 85 | 0.030 |
Why?
|
| Kidney | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2013 | 117 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2013 | 159 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4270 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2011 | 75 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2011 | 100 | 0.020 |
Why?
|
| Child | 2 | 2024 | 24617 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 283 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 300 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1048 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 859 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2011 | 287 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 1253 | 0.020 |
Why?
|
| Infant | 1 | 2024 | 12604 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1427 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1802 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 1362 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1134 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2818 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 879 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 1203 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2017 | 3056 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3605 | 0.010 |
Why?
|
| Algorithms | 1 | 2011 | 1633 | 0.010 |
Why?
|